Stockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) T-cell therapy delivery across Europe, with healthcare system utilisation rates of the therapy ...

Gilead Sciences, Inc. (NASDAQ:GILD)  plans to present over 20 research abstracts—spanning both Gilead and its cell therapy unit Kite—at two major medical conferences: the 2025 ASCO Annual Meeting (May ...

After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit. Kite has agreed to acquire all ...

Gilead has thrown plenty of money at its oncology division - for example, the $21bn acquisition of Immunomedics, $4.9bn buyout of Forty Seven, and $12bn paid for Kite Pharma, yet in Q1 the ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV pre-exposure prophylaxis (PrEP) med lenacapavir. The twice-yearly PrEP ...

Nikos Pekiaridis / NurPhoto via Getty Images Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined. The biopharma's profit got a lift from ...

Gilead's in-line product sales, slight EPS beat and lower expenses were "positive," while the key catalyst for the company's shares will be a "clean and smooth approval" in the United States of ...

Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion FOSTER CITY, Calif., April 24, 2025--(BUSINESS WIRE)--Gilead ...

Oppenheimer says Gilead (GILD) provided a “welcome surprise” this morning with ASCENT-04 hitting its primary endpoint. The firm was not expecting the readout until after ASCENT-03. ASCENT-04 ...

Gilead Sciences to Pay $202 Million in US Settlement Over HIV Drug Kickbacks By Jonathan Stempel NEW YORK (Reuters) -Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit ...

Yellow Kite has unveiled a new logo and strapline – “books for life” – to mark the lifestyle and wellbeing imprint’s 10th year of publishing. Founded in 2014, the imprint has published ...